Trade Viatris Inc. - VTRS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Viatris Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 11.2 |
| Open* | 11.24 |
| 1-Year Change* | 16.84% |
| Day's Range* | 11.23 - 11.31 |
| 52 wk Range | 8.74-12.49 |
| Average Volume (10 days) | 12.65M |
| Average Volume (3 months) | 191.22M |
| Market Cap | 13.52B |
| P/E Ratio | 7.47 |
| Shares Outstanding | 1.20B |
| Revenue | 15.47B |
| EPS | 1.51 |
| Dividend (Yield %) | 4.25909 |
| Beta | 1.12 |
| Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 22, 2024 | 11.20 | -0.09 | -0.80% | 11.29 | 11.30 | 11.18 |
| Apr 19, 2024 | 11.22 | 0.15 | 1.36% | 11.07 | 11.27 | 11.06 |
| Apr 18, 2024 | 11.08 | 0.04 | 0.36% | 11.04 | 11.21 | 11.04 |
| Apr 17, 2024 | 11.06 | -0.10 | -0.90% | 11.16 | 11.21 | 11.06 |
| Apr 16, 2024 | 11.08 | -0.15 | -1.34% | 11.23 | 11.23 | 11.02 |
| Apr 15, 2024 | 11.28 | -0.18 | -1.57% | 11.46 | 11.60 | 11.23 |
| Apr 12, 2024 | 11.28 | -0.24 | -2.08% | 11.52 | 11.53 | 11.16 |
| Apr 11, 2024 | 11.53 | -0.12 | -1.03% | 11.65 | 11.68 | 11.49 |
| Apr 10, 2024 | 11.67 | 0.07 | 0.60% | 11.60 | 11.72 | 11.59 |
| Apr 9, 2024 | 11.78 | 0.09 | 0.77% | 11.69 | 11.80 | 11.66 |
| Apr 8, 2024 | 11.71 | -0.01 | -0.09% | 11.72 | 11.86 | 11.65 |
| Apr 5, 2024 | 11.76 | 0.12 | 1.03% | 11.64 | 11.79 | 11.60 |
| Apr 4, 2024 | 11.71 | -0.34 | -2.82% | 12.05 | 12.10 | 11.69 |
| Apr 3, 2024 | 11.99 | 0.13 | 1.10% | 11.86 | 12.19 | 11.86 |
| Apr 2, 2024 | 11.91 | 0.09 | 0.76% | 11.82 | 11.96 | 11.77 |
| Apr 1, 2024 | 11.89 | -0.03 | -0.25% | 11.92 | 11.92 | 11.75 |
| Mar 28, 2024 | 11.90 | 0.05 | 0.42% | 11.85 | 11.98 | 11.74 |
| Mar 27, 2024 | 11.79 | 0.13 | 1.11% | 11.66 | 11.82 | 11.60 |
| Mar 26, 2024 | 11.56 | -0.26 | -2.20% | 11.82 | 11.91 | 11.55 |
| Mar 25, 2024 | 11.79 | -0.06 | -0.51% | 11.85 | 11.96 | 11.78 |
Viatris Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, May 6, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 Viatris Inc Earnings Release Q1 2024 Viatris Inc Earnings ReleaseForecast -Previous - |
| Monday, August 5, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 Viatris Inc Earnings Release Q2 2024 Viatris Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 16262.7 | 17886.3 | 11946 | 11500.5 | 11433.9 |
| Revenue | 16262.7 | 17886.3 | 11946 | 11500.5 | 11433.9 |
| Cost of Revenue, Total | 9230.2 | 11326.4 | 7404.2 | 6948.6 | 6861.9 |
| Gross Profit | 7032.5 | 6559.9 | 4541.8 | 4551.9 | 4572 |
| Total Operating Expense | 14651.6 | 17928.3 | 12173.6 | 10795.7 | 10553.7 |
| Selling/General/Admin. Expenses, Total | 3605.9 | 3893.6 | 2571.4 | 2416.9 | 2274.3 |
| Research & Development | 659.8 | 654.6 | 507.5 | 518.8 | 568.7 |
| Unusual Expense (Income) | 1155.7 | 2053.7 | 1690.5 | 911.4 | 848.8 |
| Operating Income | 1611.1 | -42 | -227.6 | 704.8 | 880.2 |
| Interest Income (Expense), Net Non-Operating | -592.4 | -700.2 | -548.4 | -587.3 | -566.2 |
| Other, Net | 1794.5 | 77.8 | 54.8 | 36.9 | -15.6 |
| Net Income Before Taxes | 2813.2 | -664.4 | -721.2 | 154.4 | 298.4 |
| Net Income After Taxes | 2078.6 | -1269.1 | -669.9 | 16.8 | 338 |
| Minority Interest | |||||
| Net Income Before Extra. Items | 2078.6 | -1269.1 | -669.9 | 16.8 | 338 |
| Net Income | 2078.6 | -1269.1 | -669.9 | 16.8 | 352.5 |
| Income Available to Common Excl. Extra. Items | 2078.6 | -1269.1 | -669.9 | 16.8 | 338 |
| Income Available to Common Incl. Extra. Items | 2078.6 | -1269.1 | -669.9 | 16.8 | 352.5 |
| Diluted Net Income | 2078.6 | -1269.1 | -669.9 | 16.8 | 352.5 |
| Diluted Weighted Average Shares | 1217.4 | 1208.8 | 601.2 | 516.5 | 516.5 |
| Diluted EPS Excluding Extraordinary Items | 1.70741 | -1.04988 | -1.11427 | 0.03253 | 0.6544 |
| Diluted Normalized EPS | 2.41664 | 0.05444 | 0.71345 | 1.1795 | 1.72259 |
| Total Extraordinary Items | 14.5 | ||||
| Dividends per Share - Common Stock Primary Issue | 0.48 | 0.33 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 3918.6 | 3729.1 | 3876 | 4078.2 | 4116.8 |
| Revenue | 3918.6 | 3729.1 | 3876 | 4078.2 | 4116.8 |
| Cost of Revenue, Total | 2197.1 | 2100.2 | 2285.9 | 2236 | 2350.5 |
| Gross Profit | 1721.5 | 1628.9 | 1590.1 | 1842.2 | 1766.3 |
| Total Operating Expense | 3615.2 | 3351.1 | 4072.9 | 3524.4 | 3568.5 |
| Selling/General/Admin. Expenses, Total | 954 | 884.7 | 1056.4 | 891.8 | 838.2 |
| Research & Development | 207.9 | 180.9 | 180.9 | 174.9 | 162 |
| Unusual Expense (Income) | 256.2 | 185.3 | 549.7 | 221.7 | 217.8 |
| Operating Income | 303.4 | 378 | -196.9 | 553.8 | 548.3 |
| Interest Income (Expense), Net Non-Operating | -143.7 | -147 | -147.1 | -153.2 | -145.8 |
| Other, Net | 173.3 | 91.7 | 1812.9 | 26.9 | -13.2 |
| Net Income Before Taxes | 333 | 322.7 | 1468.9 | 427.5 | 389.3 |
| Net Income After Taxes | 264 | 224.7 | 1011.2 | 354.3 | 313.9 |
| Net Income Before Extra. Items | 264 | 224.7 | 1011.2 | 354.3 | 313.9 |
| Net Income | 264 | 224.7 | 1011.2 | 354.3 | 313.9 |
| Income Available to Common Excl. Extra. Items | 264 | 224.7 | 1011.2 | 354.3 | 313.9 |
| Income Available to Common Incl. Extra. Items | 264 | 224.7 | 1011.2 | 354.3 | 313.9 |
| Diluted Net Income | 264 | 224.7 | 1011.2 | 354.3 | 313.9 |
| Diluted Weighted Average Shares | 1203.5 | 1205.6 | 1221.3 | 1218.1 | 1217.1 |
| Diluted EPS Excluding Extraordinary Items | 0.21936 | 0.18638 | 0.82797 | 0.29086 | 0.25791 |
| Dividends per Share - Common Stock Primary Issue | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Diluted Normalized EPS | 0.38989 | 0.2934 | 1.1471 | 0.4417 | 0.4022 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 10635.4 | 10902.9 | 12867.5 | 6757.3 | 6367.7 |
| Cash and Short Term Investments | 1337.8 | 790.4 | 929.3 | 541.4 | 445.6 |
| Cash & Equivalents | 1259.9 | 701.2 | 844.4 | 475.6 | 388.1 |
| Short Term Investments | 77.9 | 89.2 | 84.9 | 65.8 | 57.5 |
| Total Receivables, Net | 3814.5 | 4266.4 | 4843.8 | 3058.8 | 2881 |
| Accounts Receivable - Trade, Net | 3243.8 | 3774.4 | 3891.3 | 2640.1 | 2416.5 |
| Total Inventory | 3519.5 | 3977.7 | 5471.9 | 2670.9 | 2580.2 |
| Prepaid Expenses | 194.6 | 256.7 | 267.8 | 156.7 | 130.6 |
| Other Current Assets, Total | 1769 | 1611.7 | 1354.7 | 329.5 | 330.3 |
| Total Assets | 50022.2 | 54842.8 | 61553 | 31255.5 | 32734.9 |
| Property/Plant/Equipment, Total - Net | 3283.8 | 3479.4 | 3783.5 | 2404.2 | 2170.2 |
| Property/Plant/Equipment, Total - Gross | 5343.1 | 5879.9 | 6045.5 | 4377.5 | 3974.5 |
| Accumulated Depreciation, Total | -2059.3 | -2400.5 | -2262 | -1973.3 | -1804.3 |
| Goodwill, Net | 10425.8 | 12113.7 | 12347 | 9590.6 | 9747.8 |
| Intangibles, Net | 22607.1 | 26134.2 | 29683.2 | 11649.9 | 13664.6 |
| Long Term Investments | 94 | 0 | 47.9 | 92.2 | 138.7 |
| Other Long Term Assets, Total | 2976.1 | 2212.6 | 2823.9 | 761.3 | 645.9 |
| Total Current Liabilities | 6746.2 | 9884.4 | 10562.9 | 5569.1 | 4587.8 |
| Accounts Payable | 1158 | 1056.1 | 1345.7 | 1528.1 | 1617 |
| Accrued Expenses | 2188.9 | 3226.4 | 2735.9 | 1563.6 | 1279.2 |
| Notes Payable/Short Term Debt | 0 | 1493 | 1100.9 | 0 | 1.9 |
| Current Port. of LT Debt/Capital Leases | 1250.5 | 1860.3 | 2256.3 | 1457.6 | 655.2 |
| Other Current Liabilities, Total | 2148.8 | 2248.6 | 3124.1 | 1019.8 | 1034.5 |
| Total Liabilities | 28949.9 | 34350.1 | 38598.9 | 19371.7 | 20567.8 |
| Total Long Term Debt | 18015.2 | 19717.1 | 22429.2 | 11214.3 | 13161.2 |
| Long Term Debt | 18015.2 | 19717.1 | 22429.2 | 11214.3 | 13161.2 |
| Deferred Income Tax | 2432 | 2815 | 3123.7 | 1627.5 | 1722 |
| Minority Interest | |||||
| Other Liabilities, Total | 1756.5 | 1933.6 | 2483.1 | 960.8 | 1096.8 |
| Total Equity | 21072.3 | 20492.7 | 22954.1 | 11883.8 | 12167.1 |
| Common Stock | 12.1 | 12.1 | 12.1 | 6.1 | 6 |
| Additional Paid-In Capital | 18645.8 | 18536.1 | 18438.8 | 8643.5 | 8591.4 |
| Retained Earnings (Accumulated Deficit) | 5175.6 | 3688.8 | 5361.2 | 6031.1 | 6010.7 |
| Treasury Stock - Common | 0 | -999.7 | -999.7 | ||
| Unrealized Gain (Loss) | -2.3 | 0 | 1.2 | 0.6 | 0 |
| Other Equity, Total | -2758.9 | -1744.3 | -859.2 | -1797.8 | -1441.3 |
| Total Liabilities & Shareholders’ Equity | 50022.2 | 54842.8 | 61553 | 31255.5 | 32734.9 |
| Total Common Shares Outstanding | 1213.79 | 1209.51 | 1206.9 | 516.149 | 515.799 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 10932 | 9778 | 9630.3 | 10635.4 | 10487.8 |
| Cash and Short Term Investments | 1389.8 | 711.4 | 587.6 | 1337.8 | 721 |
| Cash & Equivalents | 1309.6 | 629.2 | 506.6 | 1259.9 | 646.7 |
| Short Term Investments | 80.2 | 82.2 | 81 | 77.9 | 74.3 |
| Total Receivables, Net | 3738.5 | 3607.3 | 3497.5 | 3814.5 | 3333.9 |
| Accounts Receivable - Trade, Net | 3231 | 3123.7 | 3021.9 | 3243.8 | 2829.8 |
| Total Inventory | 3671.9 | 3641.5 | 3664.3 | 3519.5 | 3380.4 |
| Prepaid Expenses | 334.4 | 370.6 | 239.7 | 194.6 | 237.1 |
| Other Current Assets, Total | 1797.4 | 1447.2 | 1641.2 | 1769 | 2815.4 |
| Total Assets | 48742.6 | 48695.2 | 49290.2 | 50022.2 | 48662.6 |
| Property/Plant/Equipment, Total - Net | 3174.3 | 3233.6 | 3261.6 | 3283.8 | 3303.2 |
| Property/Plant/Equipment, Total - Gross | 5284.8 | 5296.6 | 5398.9 | 5343.1 | 5282.8 |
| Accumulated Depreciation, Total | -2110.5 | -2063 | -2137.3 | -2059.3 | -1979.6 |
| Goodwill, Net | 10278.1 | 10532.5 | 10573.2 | 10425.8 | 10054.6 |
| Intangibles, Net | 21280.5 | 22084.4 | 22701.6 | 22607.1 | 23013.3 |
| Long Term Investments | 165.7 | 154.2 | 94 | ||
| Other Long Term Assets, Total | 2912 | 2912.5 | 3123.5 | 2976.1 | 1803.7 |
| Total Current Liabilities | 6834 | 6523.8 | 6108.1 | 6746.2 | 6521.4 |
| Accounts Payable | 1218.5 | 1309.6 | 1415.4 | 1158 | 791.2 |
| Accrued Expenses | 2231.3 | 2001 | 2130.1 | 2188.9 | 2271 |
| Notes Payable/Short Term Debt | 0.1 | 23.2 | 204.6 | 0 | 500.4 |
| Current Port. of LT Debt/Capital Leases | 1298.7 | 1325.6 | 500.1 | 1250.5 | 755 |
| Other Current Liabilities, Total | 2085.4 | 1864.4 | 1857.9 | 2148.8 | 2203.8 |
| Total Liabilities | 27877 | 27851.9 | 28362.3 | 28949.9 | 29480.3 |
| Total Long Term Debt | 17076.9 | 17246 | 18069.4 | 18015.2 | 18724.5 |
| Long Term Debt | 17076.9 | 17246 | 18069.4 | 18015.2 | 18724.5 |
| Deferred Income Tax | 2319 | 2407.8 | 2465 | 2432 | 2489.3 |
| Other Liabilities, Total | 1647.1 | 1674.3 | 1719.8 | 1756.5 | 1745.1 |
| Total Equity | 20865.6 | 20843.3 | 20927.9 | 21072.3 | 19182.3 |
| Common Stock | 12.2 | 12.2 | 12.2 | 12.1 | 12.1 |
| Additional Paid-In Capital | 18760.7 | 18719.4 | 18679.6 | 18645.8 | 18616.8 |
| Retained Earnings (Accumulated Deficit) | 5553 | 5369.1 | 5252.5 | 5175.6 | 4312.5 |
| Unrealized Gain (Loss) | -2.5 | -1.3 | -1.6 | -2.3 | -2.7 |
| Other Equity, Total | -3206 | -3004.3 | -2763 | -2758.9 | -3756.4 |
| Total Liabilities & Shareholders’ Equity | 48742.6 | 48695.2 | 49290.2 | 50022.2 | 48662.6 |
| Total Common Shares Outstanding | 1199.66 | 1199.15 | 1198.98 | 1213.79 | 1212.65 |
| Treasury Stock - Common | -251.8 | -251.8 | -251.8 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 2078.6 | -1269.1 | -669.9 | 16.8 | 352.5 |
| Cash From Operating Activities | 2952.6 | 3016.9 | 1231.8 | 1803.7 | 2341.7 |
| Cash From Operating Activities | 3027.6 | 4506.5 | 2216.1 | 2019.3 | 2109.9 |
| Deferred Taxes | -25.9 | 675.7 | -213.2 | -192.6 | -264.3 |
| Non-Cash Items | -1205.1 | 908.6 | 595.1 | 468 | 332.6 |
| Cash Taxes Paid | 735.2 | 641.7 | 324.4 | 278.6 | 228.6 |
| Cash Interest Paid | 642.5 | 684.8 | 555.4 | 470.6 | 460.8 |
| Changes in Working Capital | -922.6 | -1804.8 | -696.3 | -507.8 | -189 |
| Cash From Investing Activities | 1520.5 | -117.8 | -301.1 | -525.4 | -1210.4 |
| Capital Expenditures | -443 | -509.4 | -681.2 | -406 | -1195.6 |
| Other Investing Cash Flow Items, Total | 1963.5 | 391.6 | 380.1 | -119.4 | -14.8 |
| Cash From Financing Activities | -3877.9 | -3012 | -605.7 | -1169 | -1090.9 |
| Financing Cash Flow Items | -19.5 | -513.9 | -205 | -74.2 | -45 |
| Issuance (Retirement) of Stock, Net | 3.3 | 0 | 0.6 | 8.1 | -414.2 |
| Issuance (Retirement) of Debt, Net | -3280.1 | -2099.1 | -401.3 | -1102.9 | -631.7 |
| Foreign Exchange Effects | -38.9 | -30.9 | 33.8 | -7.5 | -21 |
| Net Change in Cash | 556.3 | -143.8 | 358.8 | 101.8 | 19.4 |
| Total Cash Dividends Paid | -581.6 | -399 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 224.7 | 2078.6 | 1067.4 | 713.1 | 399.2 |
| Cash From Operating Activities | 971.2 | 2952.6 | 2810 | 1941 | 1138.5 |
| Cash From Operating Activities | 730 | 3027.6 | 2157.8 | 1458.3 | 736 |
| Deferred Taxes | -26.7 | -25.9 | -179.5 | -157.6 | -52.8 |
| Non-Cash Items | 74.6 | -1205.1 | 285.7 | 71.5 | 71.2 |
| Changes in Working Capital | -31.4 | -922.6 | -521.4 | -144.3 | -15.1 |
| Cash From Investing Activities | -749.5 | 1520.5 | -264 | -149 | -66.9 |
| Capital Expenditures | -82.5 | -443 | -277.1 | -161.4 | -71.9 |
| Other Investing Cash Flow Items, Total | -667 | 1963.5 | 13.1 | 12.4 | 5 |
| Cash From Financing Activities | -974.7 | -3877.9 | -2547.3 | -1788.6 | -1009 |
| Financing Cash Flow Items | -36.3 | -19.5 | -34.5 | -33.6 | -26 |
| Issuance (Retirement) of Stock, Net | -249.1 | 3.3 | 2.5 | 0.7 | |
| Issuance (Retirement) of Debt, Net | -545.5 | -3280.1 | -2079.2 | -1465.1 | -837.9 |
| Foreign Exchange Effects | 1.2 | -38.9 | -54.5 | -40.2 | -11.4 |
| Net Change in Cash | -751.8 | 556.3 | -55.8 | -36.8 | 51.2 |
| Total Cash Dividends Paid | -143.8 | -581.6 | -436.1 | -290.6 | -145.1 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Viatris Inc. Company profile
Viatris (VTRS) is a global healthcare company. It was formed in 2020 through the merger of Pfizer’s (PFE) off-patent branded and generic medicines division Upjohn and pharmaceutical firm Mylan.
The merger of Mylan and Upjohn was announced in July 2019 and received final regulatory clearance in October 2020. Pfizer shareholders own 57% of Viatris and Mylan shareholders own 43%, according to the merger announcement. Viatris started trading on the Nasdaq Stock Exchange under the ticker VTRS in November 2020.
Viatris is headquartered in Canonsburg, Pittsburgh, US. The company is operational in over 165 countries and has global centres in Shanghai, China and Hyderabad, India.
Viatris operates about 40 manufacturing sites which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. The firm also produces numerous complex generics, biosimilars and global key brands.
Viatris offers treatment options across more than 10 major therapeutic areas covering a wide variety of non-communicable and infectious diseases. According to the company’s website, 50% of its total active pharmaceutical ingredient (API) capacity is devoted to antiretroviral (ARV), which is used against HIV infection.
Some of the well-known and key brands under Viatris are anxiety treatment drug Xanax, antidepressant Zoloft, anti-inflammatory drug Celebrex and erectile dysfunction therapy Viagra, among others. Viatris also offers global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.
| Industry: | Pharmaceuticals (NEC) |
1000 Mylan Boulevard
CANONSBURG
PENNSYLVANIA 15317
US
Income Statement
- Annual
- Quarterly
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com